Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Alamar Biosciences in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Alamar Biosciences’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-213424
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total cost of revenue | 11,578 | 6,702 |
| Gross profit | 14,457 | 6,389 |
| Operating expenses: | ||
| Research and development | 13,017 | 8,302 |
| Selling, general and administrative | 13,787 | 6,640 |
| Total operating expenses | 26,804 | 14,942 |
| Loss from operations | (12,347) | (8,553) |
| Interest income, net | 539 | 786 |
Item 1. Financial Statements
FAQ
- What is Alamar Biosciences's R&D?
- Alamar Biosciences (ALMR) reported R&D of $13.02M in Q1 2026.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Alamar Biosciences's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude